Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Multipotency of Hematopoietic Stem Cells

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Homozygous kinase-dead Csf1r mutation in outbred mice reveals essential and redundant functions of tissue resident macrophages.

Journal of leukocyte biology·2026

Same author

Authors' reply to 'Comments on dose-dependent impairment of brain functional and microstructural connectivity during leukaemia chemotherapy'.

British journal of haematology·2026

Same author

Single cell long read genotyping of transcripts reveals discrete mechanisms of clonal evolution in post-MPN AML.

Blood advances·2026

Same author

Dose-dependent impairment of brain functional and microstructural connectivity during leukaemia chemotherapy.

British journal of haematology·2026

Same author

CD38+ monocytes fuel fibrosis in myeloproliferative neoplasm.

Blood·2026

Same author

Decoding RNA modifications to unlock new treatments for AML.

Blood·2025

Same journal

Retraction: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.

The Journal of experimental medicine·2026

Same journal

Intravesical mesothelin-based CAR T cells targeting MUC16 effectively control bladder cancer in preclinical models.

The Journal of experimental medicine·2026

Same journal

Flawed translation triggers oncogenic B-T cell communication.

The Journal of experimental medicine·2026

Same journal

Correction: LCK'ed in: Inborn errors of immunity in LCK reveal how TCR signaling is calibrated.

The Journal of experimental medicine·2026

Same journal

Mechanobiology of inflammation: Pulling the strings of innate immunity.

The Journal of experimental medicine·2026

Same journal

Bile acid retention in efferocytic macrophages shapes their inflammatory status during cholangitis.

The Journal of experimental medicine·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Nov 30, 2025

Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins

Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins

Published on: June 14, 2018

A knockout combination for MPN stem cells.

Megan Bywater^1,2, Steven W Lane^1,2,3

¹Cancer Program, QIMR Berghofer Medical Research Institute, Herston, Australia.

The Journal of Experimental Medicine

|November 13, 2020

Summary

This summary is machine-generated.

This study shows combining arsenic and interferon alpha effectively targets myeloproliferative neoplasms (MPNs) stem cells. This breakthrough offers new hope for curing MPN blood cancers.

More Related Videos

Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells

Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells

Published on: July 16, 2011

Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting

Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting

Published on: June 18, 2018

Related Experiment Videos

Last Updated: Nov 30, 2025

Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins

Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins

Published on: June 14, 2018

Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells

Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells

Published on: July 16, 2011

Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting

Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting

Published on: June 18, 2018

Area of Science:

Hematology
Oncology
Stem Cell Biology

Background:

Myeloproliferative neoplasms (MPNs) are stem cell-driven blood cancers.
Targeting MPN stem cells is crucial for achieving a cure.

Purpose of the Study:

To investigate the efficacy of a combination therapy targeting MPN stem cells.
To evaluate arsenic and interferon alpha as a potential treatment for MPNs.

Main Methods:

Utilized a combination of arsenic and interferon alpha.
Focused on eliminating myeloproliferative neoplasms stem cell populations.

Main Results:

The combined therapy demonstrated a significant impact on MPN stem cells.
This approach provides a potential strategy for eradicating the root cause of MPNs.

Conclusions:

Arsenic and interferon alpha combination therapy shows promise for curing MPNs.
This research offers new hope for patients with myeloproliferative neoplasms.